ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • MSME Summit
  • Trending News
    • Viral News
    • Travel
    • People
    • Entertainment
    • Sports
  • More ...
    • VIDEOS
    • PHOTOS
BREAKING NEWS
  • New Virus in China 2022: Langya ALERT! No vaccine, no treatment!
  • Policybazaar system vulnerabilities exposed customers' personal details, says this report
  • Government removes cap on airfares with effect from 31 August
  • Samsung Galaxy Z Fold 4, Galaxy Z Flip 4, Watch 5 series, Buds 2 Pro revealed - price, India availability, specs and more
  • Maruti Suzuki Alto K10 2022 bookings open; Check token amount and how to book online
Read in App
Business News » World News

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App

Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker`s 143-year history. The price represents a 68 percent premium to Loxo`s Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner.

Loxo shares surged 66 percent to $232.65, close to the offer price of $235 per share, and prompted stock price rises for a other small developers of targeted cancer therapies, including Array BioPharma , Blueprint Medicines Corp and Clovis Oncology Inc . Lilly shares rose 0.5 percent to $115.28.

The cash deal comes on the heels of Bristol-Myers Squibb Co`s agreement last week to buy Celgene Corp for $74 billion in the largest pharmaceutical deal ever, spurring investors` hopes of a new wave of large healthcare acquisitions.

Loxo gained prominence in 2017 - just three years after going public - with impressive clinical trial results showing its drug to be highly effective on cancers driven by a single gene mutation known as TRK fusion, regardless of where in the body the tumours originated.

These patients, with more than 17 different types of advanced cancer but all with the same genetic mutation, had run out of other treatment options. Yet some 80 percent who received Loxo`s first drug, a pill called larotrectinib, experienced dramatic, often long-term improvement.

The Connecticut-based company won U.S. approval in November for the treatment under the brand name Vitrakvi, which is sold in partnership with Bayer AG . Lilly said it "very much" wants to continue the agreement with Bayer, which sells Vitrakvi outside the United States and shares U.S. commercial costs and profits with Loxo.

Loxo is also developing LOXO-292 targeting a different rare gene mutation, and analysts have forecast eventual annual sales of over $1 billion. Lilly would gain full control of that drug as it is not part of Loxo`s Bayer collaboration.

In an interview, Lilly Chief Executive David Ricks said that drug targeting a mutation known as RET, seen in thyroid, lung and other cancers, was a major driver of the deal. It received breakthrough therapy designation from U.S. regulators, which could speed its path to approval.

Loxo was quick to take advantage of new technologies that can isolate genetic drivers of tumor growth, and the willingness of regulators to approve treatments across tumor types when a specific defect is present, Ricks said at the annual JPMorgan Healthcare Conference in San Francisco on Monday.

"Loxo sort of predicted that and then capitalized on that in a way that created value," Ricks said, adding that the acquisition will help Lilly identify new targetable mutations. He said Lilly was also interested in expanding in immuno-oncology through its own research and possible deals.FINDING THE PATIENT

Targeted therapies offer the promise of potentially dramatic results if patients most likely to benefit are correctly identified, and are seen as a potential alternative to chemotherapy and its many adverse side effects.

"The acquisition of Loxo, along with last week`s acquisition of Celgene, may represent the cream of the crop in biotech being harvested by big pharma," IFS Securities analyst David Bouchey said. "The size of the deal may indicate Lilly`s willingness to pay up to out-bid the competition."

BMO Capital Markets analyst Alex Arfaei said the $8 billion valuation seemed high as Wall Street does not expect Loxo revenue to reach $1 billion until 2023.

Loxo`s drugs present the particular challenge of finding advanced cancer patients with the rare genetic mutations, which will require significantly increased use of advanced sequencing of tumours. The TRK mutation targeted by Vitrakvi only occurs in about 1 percent of patients with solid tumor cancers.

That effort got a boost last year, when the U.S. government said its Medicare programme will cover so-called next generation sequencing, which looks for hundreds of mutations across all solid tumours, for advanced cancer patients.

Lilly has typically eschewed large deals, preferring to develop its own drugs. But last year it paid $1.6 billion for Armo Biosciences, a developer of immunotherapy cancer drugs, and said in November it was open to more deals.

Lilly`s oncology portfolio includes lung cancer chemotherapy Alimta, which had third-quarter sales of $520.5 million.

Vitrakvi, priced at $32,800 per month, and experimental follow-up drug LOXO-195, on which Bayer is also a partner, together could generate annual sales of about $750 million, according to Piper Jaffray & Co.

Bayer said it does not expect the Lilly deal to impact its contract with Loxo for the time being.

Loxo`s shares have run up nearly 65 percent over the past 12 months, and ten-fold since its IPO in 2014, while Lilly`s stock has surged about 35 percent since last January.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Economy
Updated: Tue, Jan 08, 2019
04:30 am
Reuters
RELATED NEWS
Surge in credit demand, falling liquidity may lead to credit tightening: Report Surge in credit demand, falling liquidity may lead to credit tightening: Report
Government releases Rs 1.16 lakh crore of tax devolution to states Government releases Rs 1.16 lakh crore of tax devolution to states
Asian shares slip ahead of crucial US inflation data Asian shares slip ahead of crucial US inflation data
Profit of public sector banks rises 9% to Rs 15,306 crore in April-June Profit of public sector banks rises 9% to Rs 15,306 crore in April-June
India's forex reserves jump 60x since 1990s, surge 335 times since Independence | Check this data  India's forex reserves jump 60x since 1990s, surge 335 times since Independence | Check this data

LATEST NEWS

Karuvannur Cooperative bank scam: ED conducts searches in Thrissur

Raksha Bandhan 2022 correct date, best time; Rakhi Shubh Muhurat in India - Know inauspicious Bhadra, what to avoid as per Hindu calendar

Skoda Kodiaq booking reopens; check price, delivery schedule and more | Book your test drive now

Government removes cap on airfares with effect from 31 August

Bajaj Finance Fixed Deposit: Higher FD rates and quick online process - Details

Global with local! One District One Product products to be available online now

IRCTC Q1FY23 Results: Triple-digit rise in profit - key highlights; share price jumps 2%

Justice U U Lalit appointed 49th CJI, to take oath on August 27

Raju Srivastava suffers from Myocardial Infarction in gym - What led to his heart attack

SLRC Assam direct recruitment admit card Class 3, 4 released: Check direct link and exam date

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2022. India Dot Com Private Limited. All Rights Reserved.
LIVE TV